Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to $119.6 million.

  • Catalyst Pharmaceuticals' Accumulated Expenses rose 27.50% to $119.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.6 million, marking a year-over-year increase of 27.50%. This contributed to the annual value of $104.1 million for FY2024, which is 69.88% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Accumulated Expenses is $119.6 million, which was up 11.31% from $107.5 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Accumulated Expenses ranged from a high of $119.6 million in Q3 2025 and a low of $11.9 million during Q1 2021.
  • For the 3-year period, Catalyst Pharmaceuticals' Accumulated Expenses averaged around $81.4 million, with its median value being $85.2 million (2024).
  • In the last 5 years, Catalyst Pharmaceuticals' Accumulated Expenses dropped by 27.09% in 2021 and then spiked by 199.56% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $24.3 million in 2021, then skyrocketed by 120.68% to $53.6 million in 2022, then climbed by 14.28% to $61.3 million in 2023, then surged by 69.88% to $104.1 million in 2024, then grew by 27.50% to $119.6 million in 2025.
  • Its Accumulated Expenses stands at $119.6 million for Q3 2025, versus $107.5 million for Q2 2025 and $100.5 million for Q1 2025.